Short Summary
Nexus Pharmaceuticals has filed a PGR petition challenging all 30 claims of Exela Pharma Sciences' L‑cysteine parenteral nutrition patent, asserting lack of enablement, insufficient written description, and, alternatively, obviousness over the Sandoz label.
Detailed Summary
In a petition for post‑grant review of U.S. Patent No. 11,642,370, Nexus Pharmaceuticals contends that the patent’s claims covering stable L‑cysteine solutions for total parenteral nutrition are not enabled because the specification provides only narrow examples and does not teach how to achieve the broad ranges of aluminum, oxygen, pH, and concentration without undue experimentation. The petition also argues that the specification lacks a sufficient written description to support the full claim scope. As an alternative, Nexus asserts obviousness over the publicly available Sandoz label and related prior art, should the enablement arguments fail. The petition seeks cancellation of all 30 claims and references extensive district‑court findings and prior PTAB proceedings involving related patents.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Nexus Pharmaceuticals LLC vs Exela Pharma Sciences, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Wealth, Inc.vs--
Wealth, Inc. has filed a Post‑Grant Review petition seeking cancellation of all 20 claims of Vanilla Technologies’ U.S. Patent 12,353,917, alleging ineligibility, obviousness, indefiniteness, and an improper dependent claim. The petition relies on prior‑art references Racanelli, Bateman, Dintenfass, McMillen and Kwak.
Microsoft CorporationvsQomplx LLC
Microsoft has filed an IPR petition challenging 16 claims of Qomplx’s U.S. Patent 12,301,627 covering graph‑based network anomaly detection. The challenger asserts obviousness over prior‑art references Stokes, Crabtree, and Sekar under 35 U.S.C. §103.
Microsoft CorporationvsToutVirtual, Inc.
Microsoft has filed an IPR petition challenging all 20 claims of ToutVirtual’s ‘667 patent covering virtual system management, asserting obviousness over multiple prior‑art references.
Cisco Systems, Inc.vsGOLDEN EYE TECHNOLOGIES LLC
Cisco has filed an IPR petition seeking to invalidate claims 1‑3 and 13‑15 of Golden Eye Technologies' 9,717,037 patent. The challenger argues the claims are obvious over earlier Wi‑Fi standards and patents (Choudhary, Hasty, Chen). The petition requests the Board to institute the review and cancel the challenged claims.
Cisco Systems, Inc.vsGolden Eye Technologies LLC
Cisco has filed an IPR petition seeking to invalidate claims 1‑4 and 9‑11 of Golden Eye’s ’556 Wi‑Fi scanning patent, arguing that the claims are obvious over three earlier patents. The petition emphasizes that the patent was allowed despite acknowledging the same prior‑art concepts.
Pinterest, Inc.vs--
Pinterest has filed an IPR petition challenging all 20 claims of OpenTV’s ’703 patent, asserting that the claims are obvious over prior art such as Orr, Hsu, Lim, and Hervey.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.